Osteoprotegerin as a biomarker of geriatric frailty syndrome
نویسندگان
چکیده
منابع مشابه
Osteoprotegerin: A Promising Biomarker in the Metabolic Syndrome - New Perspectives
The metabolic syndrome (MS) is a cluster of cardio-metabolic alterations that has been known to increase the cardiovascular risk in these patients. The pathophysiological mechanisms underlying this observation remain unclear. In this context, osteoprotegerin (OPG) has emerged as a possible mechanism. The implication of OPG in cardiovascular disease and cardiovascular risk, the expression of thi...
متن کاملPlasma protein biomarkers of the geriatric syndrome of frailty.
Frailty is a geriatric syndrome associated with physical decline with aging. Using a proteomics-based screening method to screen plasma for potential biomarkers, we previously found inflammatory glycoproteins to be increased with frailty. The purpose of this study was to confirm if plasma levels of these glycoproteins, as well as of interleukin-6, are increased with frailty in a larger sample (...
متن کاملGrip strength as a frailty diagnostic component in geriatric inpatients
BACKGROUND Frailty has emerged as a key medical syndrome predictive of comorbidity, disability, institutionalization and death. As a component of the five frailty phenotype diagnostic criteria, patient grip strength deserves attention as a simple and objective measure of the frailty syndrome. The aim of this study was to assess conditions that influence grip strength in geriatric inpatients. ...
متن کاملOsteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications
Osteoprotegerin (OPG) is a glycoprotein involved in bone metabolisms and with a regulatory role in immune, skeletal and vascular systems. Recently, circulating OPG levels have emerged as independent biomarkers of cardiovascular disease (CVD) in patients with acute or chronic heart disease, as well as in the healthy population. Furthermore, OPG has been implicated in various inflammations and li...
متن کاملOsteoprotegerin as biomarker for persistence of rheumatoid arthritis
SIR, currently the treatment of RA is aimed at achieving low DAS remission. The ultimate aim, however, is to achieve DMARD-free sustained remission, which reflects the persistent absence of arthritis after cessation of treatment and is the closest proxy available for cure of RA. Although at present DMARD-free sustained remission can only be achieved in a minority of RA patients, recent data rev...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Aging
سال: 2019
ISSN: 1945-4589
DOI: 10.18632/aging.102083